Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | PWRM, ILMN, & CAH: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at HoldPWRM, ILMN, & CAH: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at Hold
By: Blayne Sheffield PWRM is now available for $0.033 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum. PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover: Processes - The manner in which the discoveries are made and tests developed Discoveries - Protein disease footprints, Products - Early detection tests, Biomarkers, and Drug Targets The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance: The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below: Two of Power3 Medical Areas of Research Breast Cancer Power3’s early indication breast cancer NAF protein footprint test More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer NAF footprints for individualized therapy Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders Power3’s blood serum test for distinguishing between the neurodegenerative diseases Blood serum biomarkers and drug targets for neurodegenerative disease Resistance to Chemotherapy Power3’s test for prediction of response to drug therapy in cancer Biomarkers and drug targets for treatment and monitoring of drug resistance Continue your research at www.power3medical.com ___________________________________ Recent News: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at Hold Illumina, Inc. reported the appointment of B. Melina Cimler, Ph.D., as Vice President, Quality and Regulatory Affairs, reporting to Christian Henry, Senior Vice President, Chief Financial Officer and General Manager, Life Sciences. Dr. Cimler will lead Illumina’s quality and regulatory organizations to support the development, manufacture and distribution of products serving the research, consumer and molecular diagnostic markets. Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include HiSeq 2000, an instrument for high-throughput (up to 200 Gb per run and up to 25 GB per day) sequencing using sequencing-by- For More Info Visit: http://www.illumina.com ___________________________________ Recent News: Cardinal Health deal for Healthcare Solutions OK’d Cardinal Health announced plans to expand its presence in specialty pharmaceutical services with a definitive agreement to purchase Healthcare Solutions Holding, LLC in an upfront $517 million all-cash transaction. The agreement also includes the opportunity for earn-out payments of up to $150 million over the next three years. Healthcare Solutions Holding is the parent company of a number of subsidiaries including P4 Pathways and P4 Healthcare. These businesses serve key participants across the chain of specialty care including physicians, pharmaceutical companies and payors by providing essential tools, services and data to help improve the quality of patient outcomes and increase efficiency in the delivery of health care services. The acquisition will expand Cardinal Health’s current capabilities and reach in specialty pharmaceuticals, a segment of the market which IMS Health forecasts will grow at twice the rate of traditional pharmaceuticals for the next five years and exceed $100 billion in sales by 2013. CAH is a $96 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. For more information please visit www.cardinalhealth.com ******************************************* Sign-Up For Free Stock Alerts At http://crwepicks.com/ ******************************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/ ******************************************* # # # Crown Equity Holdings Inc. assists and consults with domestic and foreign companies interested in becoming publicly traded in the U.S. The company designs and manufactures multi-monitor computer systems for financial traders and audio/video professionals. End
|
| ||||||||||||||||||||||||||||||||||||||||||
